Displaying drugs 11026 - 11050 of 11691 in total
V590
The V590 vaccine was developed on Merck’s recombinant vesicular stomatitis virus (rVSV) platform that was previously used to develop its Ebola Zaire virus vaccine, ERVEBO®[A226818, L30573, L30578]. By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one dose . Other features of...
Investigational
Matched Description: … By teaming up with IAVI, Merk developed a vaccine that does not require freezing, and only requires one ... Other features of this vaccine include potential activity with oral administration _via_ a swish-and-swallow …
MLN8054
MLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.
Investigational
MB-07803
MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. It is designed to block the metabolic pathway in the liver that is responsible for producing glucose.
Investigational
Matched Description: … MB07803 is a second generation gluconeogenesis inhibitor for the treatment of type 2 diabetes. …
Otelixizumab
Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that...
Investigational
Matched Description: … Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which …
GPI-1485
GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands.
In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without affecting normal, healthy nerves.
GPI 1485 is being studied in phase 2 clinical trials for the treatment...
Investigational
Matched Description: … GPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin …
rhIGFBP-3
rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed and is currently under phase I of the clinical trial.
Investigational
Ormeloxifene
Ormeloxifene is a third-generation selective estrogen receptor (ER) modulator. In India, ormeloxifene has been marketed since the 1990s as a non-hormonal, non-steroidal oral contraceptive taken once a week, and it was later introduced for the treatment of dysfunctional uterine bleeding. Similar to other selective estrogen receptor modulators (SERMs), ormeloxifene has...
Experimental
Matched Description: … Ormeloxifene is a third-generation selective estrogen receptor (ER) modulator. ... In India, ormeloxifene has been marketed since the 1990s as a non-hormonal, non-steroidal oral contraceptive ... [A251450,A251460] Ormeloxifene is marketed in India as a racemic mixture of the l- (levormeloxifene) …
Cariporide
Investigational
Rhamnose
A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial lipopolysaccharides. [PubChem]
Experimental
Matched Description: … A methylpentose whose L- isomer is found naturally in many plant glycosides and some gram-negative bacterial …
V24343
The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
Investigational
Matched Description: … The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's …
MBT-0312
MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.
Investigational
Matched Description: … MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving …
Denibulin
Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.
Investigational
Matched Description: … Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment …
Saredutant
Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
Investigational
Matched Description: … Saredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic …
NS-398
NS-398 is a COX-2 inhibitor. It was developed as part of the mechanistic study of the cyclooxygenases.
Experimental
Matched Description: … NS-398 is a COX-2 inhibitor. …
PF-5190457
PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations In Healthy Volunteers).
Investigational
Matched Description: … PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations …
Pexastimogene devacirepvec
Pexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma).
Investigational
Matched Description: … Pexastimogene devacirepvec is under investigation in clinical trial NCT00429312 (A Study of Recombinant …
JBPOS0101
JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients).
Investigational
Matched Description: … JBPOS0101 is under investigation in clinical trial NCT03976076 (A Study of Orally Administered JBPOS0101 …
Pecavaptan
Pecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients With Congestive Heart Failure).
Investigational
Matched Description: … Pecavaptan is under investigation in clinical trial NCT03901729 (A Trial to Study BAY1753011 in Patients …
Uliledlimab
Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for Advanced Solid Tumor).
Investigational
Matched Description: … Uliledlimab is under investigation in clinical trial NCT04322006 (A Phase I/II Study of TJ004309 for …
Glutazumab
Glutazumab is a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein exerting anti-diabetic effects.
Investigational
Matched Description: … Glutazumab is a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein exerting anti-diabetic effects …
JNJ-17216498
JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment of narcolepsy.
Investigational
Matched Description: … JNJ-17216498 is a histamine receptor H3 antagonist developed by Johnson and Johnson for the treatment …
MRG-003
MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated to monomethyl auristatin E.
Investigational
Matched Description: … MRG-003 is a recombinant humanized anti-human epidermal growth factor receptor monoclonal antibody conjugated …
CEQ508
CEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.
Investigational
Matched Description: … CEQ508 is a Live Attenuated E. …
Vamikibart
Vamikibart is under investigation in clinical trial NCT05642312 (A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema).
Investigational
Matched Description: … Vamikibart is under investigation in clinical trial NCT05642312 (A Study to Investigate Vamikibart in …
Rimiducid
Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. It was designed to overcome limitations of current cellular immunotherapies used for cancer and other blood disorders by enhancing the control of the immune cell activity and function. When administered via chemically-inducible dimerization (CID) technologies, rimiducid binds to switch proteins...
Investigational
Matched Description: … Rimiducid is a lipid-permeable tacrolimus analogue and a protein dimerizer. …
Displaying drugs 11026 - 11050 of 11691 in total